Does Atorvastatin Influence Serum C-Reactive Protein Levels in Patients on Long-Term Hemodialysis?

American Journal of Kidney Diseases

Volumn 43, Issue 3, 2004, Pages 471-478

  Vernaglione, Luigi ^a,b   Cristofano, Claudio ^a   Muscogiuri, Pietro ^a   Chimienti, Stefano ^a  

^a Nephrology and Dialysis Unit   (Italy)

^b NONE   (Italy)

Author keywords

Atorvastatin; C Reactive protein (CRP); Enzymes; Hemodialysis (HD); Serum albumin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CELLULOSE ACETATE; CHOLESTEROL; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; PLACEBO; POLYSULFONE; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DIALYSIS MEMBRANE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMOFILTRATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 1542287590     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.11.008     Document Type: Article

References (27)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
2. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000
3. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485, 2001
4. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
5. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
6. Bergstrom J, Lindholm B: Malnutrition. cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 32:834-841. 1998
7. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911. 1999
8. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation and atherosclerosis (MIA) syndrome. The heart of matter. Nephrol Dial Transplant 17:S28-S31, 2002 (suppl 11)
9. Yeun JY, Kaisen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32:S118-S125, 1998 (suppl 4)
10. Torzewski J, Torzewski M, Bowyer DE, et al: C-Reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18:1386-1392, 1998
11. Panichi V, Migliori M, De Pietro S, et al: The link of biocompatibility to cytokine production. Kidney Int Suppl 76:S96-S103, 2000
12. Schouten WEM, Grooteman MPC, van Houte AJ, Schoorl M, van Limbeek J, Nubé MJ: Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 15:379-384, 2000
13. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 60:333-340. 2001
14. Pertosa G, Grandaliano G, Gesualdo L, Schena FP: Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl 76:S104-S111, 2000
15. Buemi M, Senatore M, Corica F, et al: Are the potential non-lipid lowering uses of statins in the kidney? Nephron 89:363-368. 2001
16. Miskulin DC, Meyer KB, Martin AA, et al: Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 41:149-161, 2003
17. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
18. Kluft C, de Maat MPM, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF: Statins and C-reactive protein. Lancet 353:1274, 1999 (letter)
19. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230-235, 1999
20. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M: Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol 90:942-946, 2002
21. Plenge X, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452. 2002
22. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17:1513-1517, 2002
23. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39:1213-1217. 2002
24. van den Akker JM, Bredie SJH, Diepenveen SHA, van Tits LJH, Stalenhoef FH, van Leusen R: Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 16:238-244, 2003
25. Riesen WF, Engler H, Risch M, Korte W, Noseda G: Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23:794-799, 2002
26. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87:563-568, 2002
27. Malinowski JM: Atorvastatin: A hydroxymethylglutaryl coenzyme A reductase inhibitor. Am J Health Syst Pharm 55:2253-2267, 1998